Table 3.
Three and 5-year FFF rates from the start of any treatment with comparison of patient-, tumor- and treatment-related characteristics (univariate analysis)
| Characteristics | Events (n)/patients (n) | 3-year FFF rates - % [range] | 5-year FFF rates - % [range] |
Log-rank test |
|---|---|---|---|---|
| p-value | ||||
| Treatment |
0.0311* |
|||
| IG-IMRT |
3/49 |
95.87% [84.49%-98.95%] |
93.14% [79.96%-97.76%] |
|
| RP + IMRT |
9/49 |
87.61% [74.48%-94.24%] |
76.46% [58.31%-87.50%] |
|
| Age | ||||
| ≤ 66.8 years |
5/49 |
91.74% [79.47%-96.82%] |
88.35% [73.58%-95.12%] |
0.595 |
| > 66.8 years |
7/49 |
91.59% [79.08%-96.76%] |
83.00% [67.17%-91.65%] |
|
| Tumor stage | ||||
| T1 |
8/60 |
91.44% [80.61%-96.35%] |
84.37% [70.75%-91.99%] |
0.758 |
| T2 |
4/38 |
92.11% [77.49%-97.38%] |
87.72% [69.57%-95.38%] |
|
| Gleason score | ||||
| ≤ 6 |
5/58 |
96.52% [86.80%-99.12%] |
89.15% [75.57%-95.40%] |
0.135 |
| 7 |
7/40 |
84.68% [68.98%-92.82%] |
81.29% [64.45%-90.69%] |
|
| Pretherapeutic PSA | ||||
| ≤ 8.7 ng/mL |
4/49 |
93.83% [82.08%-97.97%] |
90.99% [77.46%-96.57%] |
0.250 |
| > 8.7 ng/mL |
8/49 |
89.55% [76.67%-95.52%] |
80.69% [64.58%-90.01%] |
|
| Concomitant ADT | ||||
| No |
12/78 |
89.53% [80.13%-94.63%] |
82.02% [70.12%-89.52%] |
0.070 |
| Yes |
0/20 |
100 [ND – ND] |
100 [ND – ND] |
|
| Adjuvant ADT | ||||
| No |
12/84 |
90.29% [81.51%-95.03%] |
83.44% [72.36%-90.36%] |
0.156 |
| Yes | 0/14 | 100 [ND – ND] | 100 [ND – ND] | |
FFF: Freedom from biochemical failure; ADT: androgen deprivation therapy; * the definition of biochemical failure in the RP + IMRT group is a PSA threshold of ≥ 0.1 ng/mL.